《NEJM,5月21日,Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-05-23
  • Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

    List of authors.

    Maximilian Ackermann, M.D., Stijn E. Verleden, Ph.D., Mark Kuehnel, Ph.D., Axel Haverich, M.D., Tobias Welte, M.D., Florian Laenger, M.D., Arno Vanstapel, Ph.D., Christopher Werlein, M.D., Helge Stark, Ph.D., Alexandar Tzankov, M.D., William W. Li, M.D., Vincent W. Li, M.D., et al.

    May 21, 2020

    DOI: 10.1056/NEJMoa2015432

    Abstract

    BACKGROUND

    Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of the disease, relatively little is known about the associated morphologic and molecular changes in the peripheral lung of patients who die from Covid-19.

    METHODS

    We examined 7 lungs obtained during autopsy from patients who died from Covid-19 and compared them with 7 lungs obtained during autopsy from patients who died from acute respiratory distress syndrome (ARDS) secondary to influenza A(H1N1) infection and 10 age-matched, uninfected control lungs. The lungs were studied with the use of seven-color immunohistochemical analysis, micro–computed tomographic imaging, scanning electron microscopy, corrosion casting, and direct multiplexed measurement of gene expression.

    RESULTS

    In patients who died from Covid-19–associated or influenza-associated respiratory failure, the histologic pattern in the peripheral lung was diffuse alveolar damage with perivascular T-cell infiltration. The lungs from patients with Covid-19 also showed distinctive vascular features, consisting of severe endothelial injury associated with the presence of intracellular virus and disrupted cell membranes. Histologic analysis of pulmonary vessels in patients with Covid-19 showed widespread thrombosis with microangiopathy. Alveolar capillary microthrombi were 9 times as prevalent in patients with Covid-19 as in patients with influenza (P<0.001). In lungs from patients with Covid-19, the amount of new vessel growth — predominantly through a mechanism of intussusceptive angiogenesis — was 2.7 times as high as that in the lungs from patients with influenza (P<0.001).

    CONCLUSIONS

    In our small series, vascular angiogenesis distinguished the pulmonary pathobiology of Covid-19 from that of equally severe influenza virus infection. The universality and clinical implications of our observations require further research to define. (Funded by the National Institutes of Health and others.)

  • 原文来源:https://www.nejm.org/doi/full/10.1056/NEJMoa2015432?query=featured_home
相关报告
  • 《5月21日_COVID-19患者的肺血管内皮炎、血栓形成和血管生成特征研究》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-05-23
    • 1.时间:2020年5月21日 2.机构或团队:德国维滕-赫德克大学、约翰内斯·古腾堡-美因茨大学医学中心、汉诺威医学院、巴塞尔大学医院、哈佛医学院等 3.事件概要: 5月21日,新英格兰医学杂志发表了来自维滕-赫德克大学、约翰内斯·古腾堡大学美因茨大学医学中心、汉诺威医学院、巴塞尔大学医院以及哈佛医学院等机构的研究团队的题为“Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19”的文章。 文章指出,在COVID-19大流行中,加剧的呼吸衰竭是死亡的主要原因。尽管科学家对COVID-19的病理生理学有着广泛的研究兴趣,但有关于COVID-19致死患者的肺周围的形态和分子变化的研究相对较少。 该研究检查了7例在尸检时获得的COVID-19死亡患者的肺并与7例死于H1N1感染继发的急性呼吸窘迫症的患者的肺以及10例年龄相匹配、未感染的对照组进行比较。肺部研究使用七色免疫组织化学分析、微计算机断层扫描成像、扫描电子显微镜、复试铸模和基因表达的直接多重测量等方法。 研究发现,在死于与COVID-19相关或与流感相关的呼吸衰竭的患者中,外周肺的组织学表现为弥漫性肺泡损伤伴血管周围T细胞浸润。来自COVID-19患者的肺部也显示出独特的血管特征,包括与细胞内病毒的存在和细胞膜破裂相关的严重内皮损伤。COVID-19患者的肺血管组织学分析显示,广泛的血栓形成伴有微血管病变。COVID-19患者的肺泡毛细血管血栓发生率是流感患者的9倍(P <0.001)。在COVID-19患者的肺中,新血管的生长量(主要是通过肠套叠性血管生成机制)是流感患者的肺的2.7倍(P <0.001)。 该研究认为,血管生成特征将COVID-19的肺部病理学与同等严重的流感病毒感染区分开。文章指出,该观察结果的普遍性和临床意义需要进一步的研究来定义。 4.附件: 原文链接https://www.nejm.org/doi/full/10.1056/NEJMoa2015432?query=featured_home
  • 《NEJM,5月22日,Remdesivir for the Treatment of Covid-19 — Preliminary Report》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-05-23
    • Remdesivir for the Treatment of Covid-19 — Preliminary Report List of authors. John H. Beigel, M.D., Kay M. Tomashek, M.D., M.P.H., Lori E. Dodd, Ph.D., Aneesh K. Mehta, M.D., Barry S. Zingman, M.D., Andre C. Kalil, M.D., M.P.H., Elizabeth Hohmann, M.D., Helen Y. Chu, M.D., M.P.H., Annie Luetkemeyer, M.D., Susan Kline, M.D., M.P.H., Diego Lopez de Castilla, M.D., M.P.H., Robert W. Finberg, M.D., et al., for the ACTT-1 Study Group Members* Article Abstract BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.